Genmab A/S re-affirmed revenue guidance for the year 2024. For the year 2024, the company?s revenue guidance is unchanged and expected to be in the range of DKK 18.7 billion to DKK 20.5 billion.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,920 DKK | -0.51% | -2.12% | -11.28% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.28% | 17.96B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+1.25% | 22.78B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B | |
+83.45% | 9.17B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S Re-Affirms Revenue Guidance for the Year 2024